Crispr Therapeutics Ag (CRSP)

$54.09 +1.00 (1.88%)
Market Cap 5.12B
Revenue (ttm) 3.51M
Net Income (ttm) -581.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16,569.80%
Debt to Equity Ratio 0.32
Volume 1,941,400
Avg Vol 1,739,136
Day's Range N/A - N/A
Shares Out 96.45M
Stochastic %K 75%
Beta 1.74
Analysts Sell
Price Target $81.10

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 561 32 77
Address:
Baarerstrasse 14, Zug, Switzerland
trendtrader6
trendtrader6 Jun. 19 at 2:31 PM
$ARKG weekly chart. Genomics starting to break out of the base. big year coming for this industry imo. $CRSP $EDIT . Any other names to add for Gene editing?
0 · Reply
Frederick_J_Frenger_Jr
Frederick_J_Frenger_Jr Jun. 18 at 7:42 PM
$CRSP I was hoping to get some company updates from Crispr by now instead of mass spam Chinese boiler room SMALL DICK broke ass daytrader PUMPER POSTS about OTHER stocks.
1 · Reply
Frederick_J_Frenger_Jr
Frederick_J_Frenger_Jr Jun. 18 at 7:30 PM
$RXRX $IBRX $SLS $NGEN $CRSP PUMPER POST nothing to do with CRSP
3 · Reply
Floridaorange
Floridaorange Jun. 18 at 5:24 PM
$RXRX Fap or no fap we are all waiting very patiently for this to explode. RXRX is currently funded into early 2028 according to management guidance, giving roughly 18–21 months of runway from today before financing becomes a major concern. $IBRX $SLS $NGEN $CRSP
3 · Reply
LibertarianTreehugger
LibertarianTreehugger Jun. 18 at 4:37 PM
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year: https://www.fool.com/investing/2026/06/18/why-crispr-therapeutics-stock-has-been-on-a-roller/ $CRSP $VRTX
0 · Reply
Steamroller_88
Steamroller_88 Jun. 18 at 3:35 PM
$CRSP
0 · Reply
handmedown1
handmedown1 Jun. 18 at 2:45 PM
$CRSP 😔 sad ... what can you say about this. Just totally a waste of investment. Maybe if CW sells this will go up. Someone is punishing this company.
0 · Reply
burbs88
burbs88 Jun. 18 at 1:49 PM
$CRSP This is moving higher without a smackdown? Surely this must be some sort of misunderstanding.
1 · Reply
Shirzo
Shirzo Jun. 18 at 10:23 AM
$NTLA NTLA is buy phase $CRSP
0 · Reply
silver2022
silver2022 Jun. 17 at 5:07 PM
$SPCX Index funds are legally required to buy a combined total of roughly 167.9 million shares of $SPCX to balance their portfolios.The Forced Index Buying Calendar says that $CRSP (Vanguard Funds)31,935,383 shares 5.00% will be buying After the close TODAY (June 17, 2026) so what do you think gonna happen? and then the other funds like $FTSE $QQQ and msci acwi will also be forced to buy soon. $SPY can't buy til mid 2027
2 · Reply
Latest News on CRSP
The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 2 days ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley

2026-06-11T10:22:50.000Z - 8 days ago

Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley

CRISPR Therapeutics AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 2:40 PM EDT - 9 days ago

CRISPR Therapeutics AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

CRISPR Therapeutics AG Transcript: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 5:40 PM EDT - 15 days ago

CRISPR Therapeutics AG Transcript: 46th Annual William Blair Growth Stock Conference

CRISPR Therapeutics AG Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:55 AM EDT - 16 days ago

CRISPR Therapeutics AG Transcript: Jefferies Global Healthcare Conference 2026

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 28, 2026, 8:00 AM EDT - 22 days ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Crispr Therapeutics price target raised to $56 from $50 at Bernstein

2026-05-13T10:36:49.000Z - 5 weeks ago

Crispr Therapeutics price target raised to $56 from $50 at Bernstein

CRISPR Therapeutics AG Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 4:40 PM EDT - 5 weeks ago

CRISPR Therapeutics AG Transcript: Bank of America Global Healthcare Conference 2026

Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI

2026-05-11T16:48:13.000Z - 5 weeks ago

Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI

Crispr Therapeutics price target raised to $82 from $80 at Citi

2026-05-07T08:40:23.000Z - 6 weeks ago

Crispr Therapeutics price target raised to $82 from $80 at Citi

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

May 6, 2026, 8:30 AM EDT - 6 weeks ago

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

Crispr Therapeutics price target lowered to $83 from $86 at BofA

2026-05-05T13:15:05.000Z - 6 weeks ago

Crispr Therapeutics price target lowered to $83 from $86 at BofA

Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)

2026-05-04T20:48:53.000Z - 6 weeks ago

Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 4, 2026, 4:30 PM EDT - 6 weeks ago

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRISPR Therapeutics AG Earnings release: Q1 2026

May 4, 2026, 4:00 PM EDT - 6 weeks ago

CRISPR Therapeutics AG Earnings release: Q1 2026

CRISPR Therapeutics AG Quarterly report: Q1 2026

May 4, 2026, 4:00 PM EDT - 6 weeks ago

CRISPR Therapeutics AG Quarterly report: Q1 2026

CRISPR Therapeutics AG Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

CRISPR Therapeutics AG Proxy statement: Proxy filing

CRISPR Therapeutics AG Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

CRISPR Therapeutics AG Proxy statement: Proxy filing

CRISPR Therapeutics AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 2:15 PM EDT - 2 months ago

CRISPR Therapeutics AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Wall Street Is Completely Wrong About These 5 Stocks

Apr 9, 2026, 1:35 PM EDT - 2 months ago

Wall Street Is Completely Wrong About These 5 Stocks

HPQ HUT NVDA RCL

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:00 AM EDT - 2 months ago

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics AG Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 2 months ago

CRISPR Therapeutics AG Proxy statement: Proxy filing

Crispr Therapeutics price target raised to $110 from $105 at Piper Sandler

2026-03-17T10:56:30.000Z - 3 months ago

Crispr Therapeutics price target raised to $110 from $105 at Piper Sandler

Cathie Wood’s ARK Investment buys 113K shares of Crispr Therapeutics today

2026-03-13T00:55:12.000Z - 3 months ago

Cathie Wood’s ARK Investment buys 113K shares of Crispr Therapeutics today

Crispr Therapeutics prices upsized convertible senior notes offering

2026-03-11T11:16:20.000Z - 3 months ago

Crispr Therapeutics prices upsized convertible senior notes offering

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Mar 11, 2026, 7:00 AM EDT - 3 months ago

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Cathie Wood’s ARK Investment buys 281K shares of Crispr Therapeutics today

2026-03-11T01:05:09.000Z - 3 months ago

Cathie Wood’s ARK Investment buys 281K shares of Crispr Therapeutics today

Crispr Therapeutics falls -9.2%

2026-03-10T16:05:15.000Z - 3 months ago

Crispr Therapeutics falls -9.2%

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Mar 10, 2026, 7:00 AM EDT - 3 months ago

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

CRISPR Therapeutics AG Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:10 AM EST - 3 months ago

CRISPR Therapeutics AG Transcript: TD Cowen 46th Annual Health Care Conference

CRISPR Therapeutics AG Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 18, 2026, 10:45 AM EST - 4 months ago

CRISPR Therapeutics AG Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:30 PM EST - 4 months ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

CRISPR Therapeutics AG Annual report: Q4 2025

Feb 12, 2026, 4:00 PM EST - 4 months ago

CRISPR Therapeutics AG Annual report: Q4 2025

CRISPR Therapeutics AG Earnings release: Q4 2025

Feb 12, 2026, 4:00 PM EST - 4 months ago

CRISPR Therapeutics AG Earnings release: Q4 2025

CRISPR Therapeutics AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 5 months ago

CRISPR Therapeutics AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics AG Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 5 months ago

CRISPR Therapeutics AG Slides: 44th Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Jan 12, 2026, 8:36 AM EST - 5 months ago

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 5 months ago

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

Dec 22, 2025, 8:30 AM EST - 6 months ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

CRISPR Therapeutics AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 11:30 AM EST - 7 months ago

CRISPR Therapeutics AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 7 months ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

CRISPR Therapeutics AG Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 7 months ago

CRISPR Therapeutics AG Earnings release: Q3 2025

CRISPR Therapeutics AG Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 7 months ago

CRISPR Therapeutics AG Quarterly report: Q3 2025

CRISPR Therapeutics AG Slides: Corporate presentation

Nov 9, 2025, 7:00 AM EST - 7 months ago

CRISPR Therapeutics AG Slides: Corporate presentation

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Nov 8, 2025, 10:03 AM EST - 7 months ago

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Nov 8, 2025, 9:56 AM EST - 7 months ago

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

Oct 10, 2025, 8:00 AM EDT - 9 months ago

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Oct 1, 2025, 8:00 AM EDT - 9 months ago

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Sep 9, 2025, 4:00 PM EDT - 10 months ago

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Sep 9, 2025, 2:22 PM EDT - 10 months ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

INCY XBI XLV

CRISPR Therapeutics AG Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 8:30 AM EDT - 10 months ago

CRISPR Therapeutics AG Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

CRISPR Therapeutics AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:30 PM EDT - 10 months ago

CRISPR Therapeutics AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:15 PM EDT - 11 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

CRISPR Therapeutics AG Quarterly report: Q2 2025

Aug 4, 2025, 12:30 PM EDT - 11 months ago

CRISPR Therapeutics AG Quarterly report: Q2 2025

CRISPR Therapeutics AG Earnings release: Q2 2025

Aug 4, 2025, 12:30 PM EDT - 11 months ago

CRISPR Therapeutics AG Earnings release: Q2 2025

The Big 3: ASML, GOOGL, CRSP

Jul 15, 2025, 12:01 PM EDT - 1 year ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Jun 26, 2025, 7:00 AM EDT - 1 year ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

The Big 3: CRSP, OKLO, GME

Jun 23, 2025, 12:01 PM EDT - 1 year ago

The Big 3: CRSP, OKLO, GME

OKLO GME

CRISPR Therapeutics AG Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 3:20 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

CRISPR Therapeutics AG Transcript: 45th Annual William Blair Growth Stock Conference

Jun 3, 2025, 12:20 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: 45th Annual William Blair Growth Stock Conference

CRISPR Therapeutics AG Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 4:00 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

CRISPR Therapeutics AG Slides: Corporate Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Slides: Corporate Presentation

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 6, 2025, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

CRISPR Therapeutics AG Quarterly report: Q1 2025

May 6, 2025, 12:30 PM EDT - 1 year ago

CRISPR Therapeutics AG Quarterly report: Q1 2025

CRISPR Therapeutics AG Earnings release: Q1 2025

May 6, 2025, 12:30 PM EDT - 1 year ago

CRISPR Therapeutics AG Earnings release: Q1 2025

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

CRISPR Therapeutics AG Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 12:45 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: 24th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Mar 26, 2025, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Announces Transition of Chief Operating Officer

CRISPR Therapeutics AG Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 10:30 AM EST - 1 year ago

CRISPR Therapeutics AG Transcript: TD Cowen 45th Annual Healthcare Conference

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 4:01 PM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CRISPR Therapeutics AG Annual report: Q4 2024

Feb 11, 2025, 4:00 PM EST - 1 year ago

CRISPR Therapeutics AG Annual report: Q4 2024

CRISPR Therapeutics AG Earnings release: Q4 2024

Feb 11, 2025, 4:00 PM EST - 1 year ago

CRISPR Therapeutics AG Earnings release: Q4 2024

CRISPR Therapeutics AG Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 2:00 PM EST - 1 year ago

CRISPR Therapeutics AG Transcript: Guggenheim SMID Cap Biotech Conference

CRISPR Therapeutics AG Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

CRISPR Therapeutics AG Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

CRISPR Therapeutics AG Slides: FY 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

CRISPR Therapeutics AG Slides: FY 2025

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 12:00 PM EST - 1 year ago

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

CRISPR Therapeutics AG Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 11:00 AM EST - 1 year ago

CRISPR Therapeutics AG Transcript: Jefferies London Healthcare Conference 2024

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

CRISPR Therapeutics AG Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 2:00 PM EST - 1 year ago

CRISPR Therapeutics AG Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 9:01 AM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

CRISPR Therapeutics AG Quarterly report: Q3 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

CRISPR Therapeutics AG Quarterly report: Q3 2024

CRISPR Therapeutics AG Earnings release: Q3 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

CRISPR Therapeutics AG Earnings release: Q3 2024

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:01 PM EDT - 2 years ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

CRISPR Therapeutics AG Quarterly report: Q2 2024

Aug 5, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Quarterly report: Q2 2024

CRISPR Therapeutics AG Earnings release: Q2 2024

Aug 5, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Earnings release: Q2 2024

CRISPR Therapeutics AG Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 11, 2024, 9:20 AM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

CRISPR Therapeutics AG Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 2:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: Jefferies 2024 Global Healthcare Conference

Final Trade: UAL, NKE, SLV & CRSP

May 24, 2024, 7:40 PM EDT - 2 years ago

Final Trade: UAL, NKE, SLV & CRSP

SLV NKE UAL

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

May 23, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

CRISPR Therapeutics AG Transcript: BofA Securities 2024 Health Care Conference

May 15, 2024, 12:20 PM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: BofA Securities 2024 Health Care Conference

CRISPR Therapeutics AG Slides: FY 2024

May 15, 2024, 12:20 PM EDT - 2 years ago

CRISPR Therapeutics AG Slides: FY 2024

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

May 9, 2024, 8:30 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

CRISPR Therapeutics AG Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Quarterly report: Q1 2024

CRISPR Therapeutics AG Earnings release: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Earnings release: Q1 2024

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

May 8, 2024, 7:00 AM EDT - 2 years ago

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 2 years ago

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics AG Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 10, 2024, 11:45 AM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: 23rd Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Mar 27, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Mar 13, 2024, 8:30 AM EDT - 2 years ago

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Final Trade: HPQ, RSG, GM, CRSP

Mar 1, 2024, 6:21 PM EST - 2 years ago

Final Trade: HPQ, RSG, GM, CRSP

GM HPQ RSG

Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed

Feb 29, 2024, 5:02 PM EST - 2 years ago

Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed

CRISPR Therapeutics AG Transcript: Citi 2024 Virtual Oncology Leadership Summit

Feb 21, 2024, 1:00 PM EST - 2 years ago

CRISPR Therapeutics AG Transcript: Citi 2024 Virtual Oncology Leadership Summit

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 7:30 AM EST - 2 years ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

CRISPR Therapeutics AG Annual report: Q4 2023

Feb 21, 2024, 7:00 AM EST - 2 years ago

CRISPR Therapeutics AG Annual report: Q4 2023

CRISPR Therapeutics AG Earnings release: Q4 2023

Feb 21, 2024, 7:00 AM EST - 2 years ago

CRISPR Therapeutics AG Earnings release: Q4 2023

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

Feb 15, 2024, 8:30 AM EST - 2 years ago

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Feb 13, 2024, 8:30 AM EST - 2 years ago

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Feb 13, 2024, 2:30 AM EST - 2 years ago

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

FDA Approves New CRISPR Gene-Editing Treatment

Jan 16, 2024, 5:59 PM EST - 2 years ago

FDA Approves New CRISPR Gene-Editing Treatment

VRTX

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Jan 16, 2024, 4:01 PM EST - 2 years ago

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

trendtrader6
trendtrader6 Jun. 19 at 2:31 PM
$ARKG weekly chart. Genomics starting to break out of the base. big year coming for this industry imo. $CRSP $EDIT . Any other names to add for Gene editing?
0 · Reply
Frederick_J_Frenger_Jr
Frederick_J_Frenger_Jr Jun. 18 at 7:42 PM
$CRSP I was hoping to get some company updates from Crispr by now instead of mass spam Chinese boiler room SMALL DICK broke ass daytrader PUMPER POSTS about OTHER stocks.
1 · Reply
Frederick_J_Frenger_Jr
Frederick_J_Frenger_Jr Jun. 18 at 7:30 PM
$RXRX $IBRX $SLS $NGEN $CRSP PUMPER POST nothing to do with CRSP
3 · Reply
Floridaorange
Floridaorange Jun. 18 at 5:24 PM
$RXRX Fap or no fap we are all waiting very patiently for this to explode. RXRX is currently funded into early 2028 according to management guidance, giving roughly 18–21 months of runway from today before financing becomes a major concern. $IBRX $SLS $NGEN $CRSP
3 · Reply
LibertarianTreehugger
LibertarianTreehugger Jun. 18 at 4:37 PM
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year: https://www.fool.com/investing/2026/06/18/why-crispr-therapeutics-stock-has-been-on-a-roller/ $CRSP $VRTX
0 · Reply
Steamroller_88
Steamroller_88 Jun. 18 at 3:35 PM
$CRSP
0 · Reply
handmedown1
handmedown1 Jun. 18 at 2:45 PM
$CRSP 😔 sad ... what can you say about this. Just totally a waste of investment. Maybe if CW sells this will go up. Someone is punishing this company.
0 · Reply
burbs88
burbs88 Jun. 18 at 1:49 PM
$CRSP This is moving higher without a smackdown? Surely this must be some sort of misunderstanding.
1 · Reply
Shirzo
Shirzo Jun. 18 at 10:23 AM
$NTLA NTLA is buy phase $CRSP
0 · Reply
silver2022
silver2022 Jun. 17 at 5:07 PM
$SPCX Index funds are legally required to buy a combined total of roughly 167.9 million shares of $SPCX to balance their portfolios.The Forced Index Buying Calendar says that $CRSP (Vanguard Funds)31,935,383 shares 5.00% will be buying After the close TODAY (June 17, 2026) so what do you think gonna happen? and then the other funds like $FTSE $QQQ and msci acwi will also be forced to buy soon. $SPY can't buy til mid 2027
2 · Reply
mikeg1999
mikeg1999 Jun. 17 at 4:28 PM
$CRSP $NTLA if there was a buyout, it’d like be REGN; same rationale as if there was a buyout for CRSP, it’d be VRTX
0 · Reply
Frederick_J_Frenger_Jr
Frederick_J_Frenger_Jr Jun. 17 at 3:49 PM
$CRSP
0 · Reply
Frederick_J_Frenger_Jr
Frederick_J_Frenger_Jr Jun. 17 at 3:47 PM
$CRSP all us long time suffering shareholders right now
0 · Reply
NwordFslur
NwordFslur Jun. 17 at 2:51 PM
$CRSP why can't you be like $NTLA?
1 · Reply
DegenStock
DegenStock Jun. 17 at 1:56 PM
$CRSP $NTLA that’s cute, just like how CRSP had buyout rumors late last year and nothing came to fruition 😂
0 · Reply
BitcoinMillionaire888
BitcoinMillionaire888 Jun. 17 at 1:53 PM
$CRSP its the $NTLA buyout rumour baby!!
0 · Reply
Stockswingalert
Stockswingalert Jun. 17 at 1:03 PM
$CLPT $CRSP https://x.com/stockswingalert/status/2067210874125783299?s=46 600% on CLPT Then nailed $QURE exact top 👇👇👇 To the penny!!!! 🎯🎯🎯🎯
0 · Reply
MF__DOOM
MF__DOOM Jun. 17 at 12:07 PM
$BLUE $CRSP $QQQ $QURE $SPY 80-100
0 · Reply
handmedown1
handmedown1 Jun. 16 at 8:00 PM
$TWST is killing it. $CRSP take a clue.
0 · Reply
ArmLee
ArmLee Jun. 16 at 6:03 PM
$RXRX Here we go! This has been following $CRSP price action today.
1 · Reply
handmedown1
handmedown1 Jun. 16 at 12:12 PM
$CRSP will they ever report anything???
1 · Reply
Frederick_J_Frenger_Jr
Frederick_J_Frenger_Jr Jun. 16 at 1:39 AM
$CRSP I was looking at long term charts for IBB, FBIOX and XBI and they are all showing some form of a monster "W" being formed going back to 2015. We can all hope, right? LOL! If it pans out we're sitting on the equivalent of the next semiconductor run or... F it, nothing will happen...
0 · Reply